As previously reported, Argus downgraded Elevance Health (ELV) to Hold from Buy with no price target Given the headwinds of higher medical costs, the company’s profit margins in the Medicaid and Medicare Advantage businesses will be under pressure for the rest of 2024 and in 2025, though the firm would review look to upgrade the stock if it sees greater stability in medical costs/acuity and more favorable adjustments to Medicaid rates from the states, the analyst tells investors in a research note. Argus is also cutting its FY24 EPS view on Elevance to $33.00 from $37.30 and to $35.00 from $41.70 in FY25.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $520 from $620 at Truist
- Elevance Health downgraded to Hold from Buy at Argus
- Elevance Health price target lowered to $555 from $605 at UBS
- Evolent weakness linked to elevated Medicaid MLRs at peers, says Stephens
- Elevance Health stock to be down LDD on ‘perfect storm,’ says Baird
Questions or Comments about the article? Write to editor@tipranks.com